merger and acquisitions
Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion
April 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions
Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
